Koers RxElite, Inc. Other OTC
Aandelen
RXEI
US78347X1054
Farmaceutische producten
Omzet 2006 | 14,17 mln. 13,07 mln. | Omzet 2007 | 2,81 mln. 2,59 mln. | Marktkapitalisatie | 84,94 mln. 78,32 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2006 | 7 mln. 6,45 mln. | Nettowinst (verlies) 2007 | -17 mln. -15,68 mln. | EV/omzet 2006 * | - |
Nettoliquiditeiten 2006 | 789K 728K | Nettoliquiditeiten 2007 | 8,6 mln. 7,93 mln. | EV/omzet 2007 | 27,1 x |
K/w-verhouding 2006 * |
-
| K/w-verhouding 2007 |
-3,2
x | Werknemers | - |
Dividendrendement 2006 * |
-
| Dividendrendement 2007 |
-
| Vrij verhandelbaar | 68,17% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Earl E. Sullivan
CEO | Chief Executive Officer | 52 | 13-07-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,91% | 41,97 mld. | |
+22,40% | 22,34 mld. | |
+18,48% | 15,25 mld. | |
+16,12% | 14 mld. | |
+45,12% | 12,06 mld. | |
-9,58% | 6,8 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+14,18% | 5,49 mld. |